Akèy › Dyabèt Tip 2 › Connecticut
Etid klinik pou Dyabèt Tip 2 nan Connecticut
14 etid pou Dyabèt Tip 2 ap chèche patisipan nan sit nan Connecticut.
Vil nan Connecticut
Tèks ofisyèl etid la (Anglè)
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
- Cardiology Physicians of Fairfield County - Bridgeport, Bridgeport
- CMR of Greater New Haven, LLC, Hamden
- Cardiology Associates of Fairfield County, Stamford
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07064473Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema
- Chase Medical Research LLC, Waterbury
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07817251A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
- New England Research Associates, LLC, Bridgeport
- CMR of Greater New Haven, LLC, Hamden
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07282600Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease
- Yale University, New Haven
Ap rekriteFaz 2
Laj 18 a 80 · Tout sèks · Mizajou Sep 11, 2026 · NCT07271186A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
- Yale School of Medicine, New Haven
Ap rekriteFaz 3
Laj 10 a 18 · Tout sèks · Mizajou Sep 9, 2026 · NCT07282613A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
- Research Site, Bridgeport
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT07662213A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus
- Research Site, Bridgeport
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 31, 2026 · NCT07662044A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
- Yale Diabetes Research, New Haven
Ap rekriteFaz 3
Laj 10 a 17 · Tout sèks · Mizajou Aug 7, 2026 · NCT06739122Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System
- Yale, New Haven
Ap rekrite
Laj 14 a 75 · Tout sèks · Mizajou Aug 3, 2026 · NCT07579702Effect of the Thrive AI Health App on Lifestyle Behaviors and Quality of Life
- Yale University, New Haven
Ap rekriteVolontè an sante akeyi
Laj 40 ak plis · Tout sèks · Mizajou Jun 17, 2026 · NCT07376655Ultrasound Effects on Glycemic Control in T2DM
- Yale-New Haven Hospital, New Haven
Ap rekrite
Laj 21 a 75 · Tout sèks · Mizajou Jan 27, 2026 · NCT05354947Continuous Glucose Monitors (CGMs) for All: Studying the Impact of Expanding CGM Access
- Fair Haven Community Health Care (FHCHC), New Haven
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Dec 3, 2025 · NCT06658067Diabetes Learning in Virtual Environments Just in Time for Community Reentry
- University of Connecticut, Storrs
- University of Connecticut, Storrs Mansfield
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Jul 28, 2025 · NCT05286892Reversibility of Brain Glucose Transport in Type 2 Diabetes Mellitus (T2DM)
- Yale New Haven Hospital (YNHH) Research Unit (HRU), New Haven
Ap rekriteVolontè an sante akeyi
Laj 18 a 60 · Tout sèks · Mizajou Jan 14, 2025 · NCT05776563Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.